دورية أكاديمية
Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis
| العنوان: | Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis |
|---|---|
| المؤلفون: | Jacky Tu, Mohammed Al Harasi, Michael Pallin, Chris Daley, Benjamin A. Rogers, Paul T. King |
| المصدر: | Heliyon, Vol 9, Iss 9, Pp e19968- (2023) |
| بيانات النشر: | Elsevier, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Science (General) LCC:Social sciences (General) |
| مصطلحات موضوعية: | Bronchiectasis, Exacerbations, Outpatient, Parenteral, Antibiotics, Science (General), Q1-390, Social sciences (General), H1-99 |
| الوصف: | Background: Patients with bronchiectasis often require hospitalisation for the administration of intravenous antibiotics for the management of acute exacerbations. Increasingly, Outpatient Parenteral Antibiotic Therapy (OPAT) services have become available as a potential alternative for domiciliary management. Aims: This study assessed outcomes in both cystic fibrosis (CF) and non-CF bronchiectasis patients who received OPAT for the management of an acute exacerbation of bronchiectasis. Methods: A retrospective study of consecutive subjects was done in both CF and non-CF groups in a large metropolitan Health Service in Australia from 2016 to 2022. Results: There were 51 episodes of care in the non-CF group (22 subjects) and 73 episodes in the CF group (13 subjects). The non-CF group were nearly all treated with once daily domiciliary intravenous (IV) ceftriaxone (49/51 episodes) for a duration of 9.1 ± 3.0 days (mean and standard deviation (SD)) via a peripherally inserted venous canula (84% of episodes). In contrast, the CF group generally received dual IV antibiotics (64% of episodes), with an average duration of 16.8 ± 6.3 days via central venous access (100%). In the non-CF group, the admission rate to hospital after 1 month was 9.6% and in the CF group was 0%. At 3 and 6 months the readmission rate for the non-CF group was 15.7% and 19.6% and CF group was 21.9% and 31.5%. There was a low rate of complications for the OPAT admissions (2% for the non-CF group and 7% for CF group). Conclusions: OPAT is a viable alternative for the management of bronchiectasis exacerbations. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2405-8440 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2405844023071761; https://doaj.org/toc/2405-8440 |
| DOI: | 10.1016/j.heliyon.2023.e19968 |
| URL الوصول: | https://doaj.org/article/95b3d65f1f9b4c9da149e6248ea3e775 |
| رقم الأكسشن: | edsdoj.95b3d65f1f9b4c9da149e6248ea3e775 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24058440 |
|---|---|
| DOI: | 10.1016/j.heliyon.2023.e19968 |